CY1114850T1 - Αντικαρκινικη ενωση και η φαρμακευτικη συνθεση που την περιεχει - Google Patents
Αντικαρκινικη ενωση και η φαρμακευτικη συνθεση που την περιεχειInfo
- Publication number
- CY1114850T1 CY1114850T1 CY20131100920T CY131100920T CY1114850T1 CY 1114850 T1 CY1114850 T1 CY 1114850T1 CY 20131100920 T CY20131100920 T CY 20131100920T CY 131100920 T CY131100920 T CY 131100920T CY 1114850 T1 CY1114850 T1 CY 1114850T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- union
- pharmaceutical composition
- composition containing
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Abstract
Η εφεύρεση σχετίζεται με την ένωση του τύπου (Ι) : πιο συγκεκριμένα με την αριστερόστροφη μορφή της (la), κυρίως αυτή που παρουσιάζει την περιστροφική ισχύ [[άλφα]] = -38,6+0,7 σε μια συγκέντρωση από 0,698 mg/ml μέσα σε μεθανόλη. Η ένωση μπορεί να υπάρχει με τη μορφή βάσης ή ενός άλατος προσθήκης σε ένα οξύ, κυρίως σε ένα φαρμακευτικώς αποδεκτό οξύ. Η ένωση αυτή είναι ένας επιλεκτικός αναστολέας των κινάσεων Αurora A και Β. Μπορεί να χρησιμοποιηθεί ως αντικαρκινικός παράγοντας.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0902392A FR2945535B1 (fr) | 2009-05-18 | 2009-05-18 | Compose anticancereux et composition pharmaceutique le contenant |
| EP10728768.2A EP2432766B1 (fr) | 2009-05-18 | 2010-05-17 | Composé anticancéreux et composition pharmaceutique le contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114850T1 true CY1114850T1 (el) | 2016-12-14 |
Family
ID=40973187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100920T CY1114850T1 (el) | 2009-05-18 | 2013-10-17 | Αντικαρκινικη ενωση και η φαρμακευτικη συνθεση που την περιεχει |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US9073917B2 (el) |
| EP (1) | EP2432766B1 (el) |
| JP (1) | JP5656981B2 (el) |
| KR (1) | KR20120032483A (el) |
| CN (1) | CN102459193B (el) |
| AR (1) | AR076686A1 (el) |
| AU (1) | AU2010251013B2 (el) |
| BR (1) | BRPI1012201A2 (el) |
| CA (1) | CA2762233C (el) |
| CL (1) | CL2011002930A1 (el) |
| CO (1) | CO6400138A2 (el) |
| CY (1) | CY1114850T1 (el) |
| DK (1) | DK2432766T3 (el) |
| EA (1) | EA021084B1 (el) |
| ES (1) | ES2430989T3 (el) |
| FR (1) | FR2945535B1 (el) |
| HK (1) | HK1167388A1 (el) |
| HR (1) | HRP20130959T1 (el) |
| IL (1) | IL216361A0 (el) |
| JO (1) | JO2852B1 (el) |
| MA (1) | MA33356B1 (el) |
| ME (1) | ME01542B (el) |
| MX (1) | MX2011012356A (el) |
| MY (1) | MY152995A (el) |
| NZ (1) | NZ596464A (el) |
| PL (1) | PL2432766T3 (el) |
| PT (1) | PT2432766E (el) |
| RS (1) | RS53002B (el) |
| SG (1) | SG176169A1 (el) |
| SI (1) | SI2432766T1 (el) |
| SM (1) | SMT201400005B (el) |
| TW (1) | TWI441822B (el) |
| UY (1) | UY32644A (el) |
| WO (1) | WO2010133794A1 (el) |
| ZA (1) | ZA201108447B (el) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2945535B1 (fr) | 2009-05-18 | 2011-06-10 | Sanofi Aventis | Compose anticancereux et composition pharmaceutique le contenant |
| FR2967413A1 (fr) * | 2010-11-17 | 2012-05-18 | Sanofi Aventis | Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora. |
| US9096594B2 (en) | 2012-10-12 | 2015-08-04 | The Broad Institute, Inc. | Kinase inhibitors and methods of use thereof |
| EA031262B1 (ru) | 2014-07-01 | 2018-12-28 | Такеда Фармасьютикал Компани Лимитед | Гетероциклические соединения и их применение в качестве ингибиторов орфанного рецептора гамма-t, родственного рецепторам ретиноидов (ror) |
| WO2018187630A1 (en) | 2017-04-05 | 2018-10-11 | The Broad Institute, Inc. | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1242422A1 (en) | 1999-11-19 | 2002-09-25 | Abbott Laboratories | Tricyclic dihydropyrimidine potassium channel openers |
| CA2437215A1 (en) | 2001-02-02 | 2002-08-15 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| RU2006100484A (ru) | 2003-06-13 | 2006-06-10 | Центарис ГмбХ, Германи (DE) | Соединения, обладающие ингибирующей активностью в отношении фосфатидилинозит-3-киназы, фармацевтическая композиция, способ определения эффективности этих соединений, способ лечения нарушений (варианты) и способ изменения передачи сигнала в клетках |
| RS51351B (en) * | 2005-07-20 | 2011-02-28 | Aventis Pharma S.A. | 1,4-DIHYDROPYRIDINE-CONDENSED HTEROCYCLES, PROCEDURES FOR THEIR PRODUCTION, USE AND THE COMPOSITIONS CONTAINING THEM |
| FR2945535B1 (fr) | 2009-05-18 | 2011-06-10 | Sanofi Aventis | Compose anticancereux et composition pharmaceutique le contenant |
-
2009
- 2009-05-18 FR FR0902392A patent/FR2945535B1/fr not_active Expired - Fee Related
-
2010
- 2010-05-16 JO JO2010163A patent/JO2852B1/en active
- 2010-05-17 EA EA201171429A patent/EA021084B1/ru not_active IP Right Cessation
- 2010-05-17 PL PL10728768T patent/PL2432766T3/pl unknown
- 2010-05-17 ME MEP-2013-121A patent/ME01542B/me unknown
- 2010-05-17 PT PT107287682T patent/PT2432766E/pt unknown
- 2010-05-17 US US13/320,965 patent/US9073917B2/en not_active Expired - Fee Related
- 2010-05-17 WO PCT/FR2010/050948 patent/WO2010133794A1/fr active Application Filing
- 2010-05-17 ES ES10728768T patent/ES2430989T3/es active Active
- 2010-05-17 AR ARP100101705A patent/AR076686A1/es unknown
- 2010-05-17 DK DK10728768.2T patent/DK2432766T3/da active
- 2010-05-17 MX MX2011012356A patent/MX2011012356A/es active IP Right Grant
- 2010-05-17 CN CN201080032327.7A patent/CN102459193B/zh not_active Expired - Fee Related
- 2010-05-17 KR KR1020117030136A patent/KR20120032483A/ko active Search and Examination
- 2010-05-17 SG SG2011085529A patent/SG176169A1/en unknown
- 2010-05-17 BR BRPI1012201A patent/BRPI1012201A2/pt not_active IP Right Cessation
- 2010-05-17 NZ NZ596464A patent/NZ596464A/en not_active IP Right Cessation
- 2010-05-17 TW TW099115713A patent/TWI441822B/zh not_active IP Right Cessation
- 2010-05-17 JP JP2012511323A patent/JP5656981B2/ja not_active Expired - Fee Related
- 2010-05-17 EP EP10728768.2A patent/EP2432766B1/fr active Active
- 2010-05-17 CA CA2762233A patent/CA2762233C/fr not_active Expired - Fee Related
- 2010-05-17 MY MYPI2011005531 patent/MY152995A/en unknown
- 2010-05-17 SI SI201030384T patent/SI2432766T1/sl unknown
- 2010-05-17 RS RS20130444A patent/RS53002B/en unknown
- 2010-05-17 MA MA34441A patent/MA33356B1/fr unknown
- 2010-05-17 AU AU2010251013A patent/AU2010251013B2/en not_active Ceased
- 2010-05-18 UY UY0001032644A patent/UY32644A/es not_active Application Discontinuation
-
2011
- 2011-11-14 IL IL216361A patent/IL216361A0/en unknown
- 2011-11-17 ZA ZA2011/08447A patent/ZA201108447B/en unknown
- 2011-11-18 CO CO11157425A patent/CO6400138A2/es active IP Right Grant
- 2011-11-18 CL CL2011002930A patent/CL2011002930A1/es unknown
-
2012
- 2012-08-15 HK HK12108002.5A patent/HK1167388A1/xx not_active IP Right Cessation
-
2013
- 2013-10-09 HR HRP20130959AT patent/HRP20130959T1/hr unknown
- 2013-10-17 CY CY20131100920T patent/CY1114850T1/el unknown
-
2014
- 2014-01-16 SM SM201400005T patent/SMT201400005B/xx unknown
-
2015
- 2015-06-02 US US14/728,846 patent/US9221817B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1114850T1 (el) | Αντικαρκινικη ενωση και η φαρμακευτικη συνθεση που την περιεχει | |
| NO2016021I1 (no) | 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2Hpyrido[2,3-D]pyrimidinderivater og relaterte forbindelser for behandling av kreft | |
| ECSP066541A (es) | Nuevos derivados de piridazin-3(2h)-ona | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| CY1112401T1 (el) | Παραγωγα πυριδαζινης | |
| CY1119730T1 (el) | Παραγωγα καρβοξυλικου οξεος πυρρολιδινης ως αγωνιστες του συζευγμενου με πρωτεϊνή-g υποδοχεα 43 (gpr43), φαρμακευτικη συνθεση και μεθοδοι για χρηση στην αντιμετωπιση μεταβολικων διαταραχων | |
| EA200970149A1 (ru) | Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии | |
| BR122013025375B8 (pt) | compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas | |
| EA200970207A1 (ru) | Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов | |
| EP1951729A4 (en) | OXYGEN-LINKED PYRIMIDINE DERIVATIVES | |
| CY1108292T1 (el) | Αντικαρκινικο σκευασμα που περιεχει dmxaa | |
| CY1116490T1 (el) | Φαρμακευτικες συνθεσεις κλεβιδιπινης και μεθοδοι για την παραγωγη συγκεντρωσεων χαμηλων προσμιξεων των ιδιων | |
| ATE507212T1 (de) | Morpholine als 5ht2c-agonisten | |
| EA201290183A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
| ECSP077402A (es) | Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica | |
| CY1115623T1 (el) | Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ | |
| EA201071329A1 (ru) | Диамидные производные адамантана и их применение | |
| UY29857A1 (es) | Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica. | |
| CY1122084T1 (el) | Συνθεσεις που περιλαμβανουν αμλοδιπινη και μπισοπρολολη | |
| MA32776B1 (fr) | Inhibiteurs de l'akt et de la p70 s6 kinase | |
| EA200700601A1 (ru) | Производные фениламинопиримидина как ингибиторы bcr-abl | |
| ECSP099442A (es) | Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona | |
| NO20085317L (no) | Imidazoazepinonforbindelser | |
| CY1113240T1 (el) | Αλατα ενωσεων αναστολεα hiv | |
| CY1122596T1 (el) | Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου |